That’s a wrap on our final DECISION GA! From COMBAT & PROSPECT updates to forward-looking discussions and feedback, we’re proud of our shared achievements and motivated to keep advancing ACLF & decompensated cirrhosis research together. #LiverSky

Our final GA is a look back and forward - from major scientific milestones to future discoveries! After a keynote by Prof. Rubén Francés, partners shared results on omics integration, biomarkers & systems medicine - and closed today with a masterclass on data repositories. #cirrhosis

Next week: the final DECISION General Assembly in Madrid! 🎉 Celebrating 5+ years of science, collaboration, & results @rautoupe.bsky.social  @concentris.bsky.social  @navarrabiomed.bsky.social  @bioeticayderecho.bsky.social  @medblab.bsky.social  @europeliver.bsky.social  @easlnews.bsky.social et al

The latest DECISION Masterclass is live! 💡 Clinical Bioinformatics – It’s More Than Pressing a Button with Núria Planell, Cristina Sanchez & David Gomez-Cabrero. Watch here: https://youtu.be/UBm1_JGhw6M #Bioinformatics #ClinicalResearch #ACLF

Today is #WorldHepatitisDay! We spotlight two DECISION partners deeply committed to #liverhealth: 🔬 @easlnews.bsky.social – advancing #hepatology research 🧡 @europeliver.bsky.social – amplifying the voice of liver patients Together, we work toward a healthier future beyond ACLF. #Cirrhosis

🔥 We’ve hit 50% recruitment in the #COMBATtrial! Huge thanks to all involved!💙 @rautoupe.bsky.social @hopitalbeaujon.bsky.social @hospitalclinic.bsky.social @rwth.bsky.social @uni-muenster.de @brunslab.bsky.social @medblab.bsky.social @frankuschner.bsky.social #LiverSky #ClinicalTrial

🎥 New keynote online! Prof. Richard Moreau, Director of #EFCLIF, explores immune dysfunction in AD & #ACLF and suggests a common mechanism behind inflammation & immune deficiency. Watch now 👉 https://youtu.be/KWoUbTsNjQM  #LiverSky #Hepatology

🎉 Exciting news: We’ve surpassed 500 followers on @linkedin.com! Follow us there for updates on trials, science, and more 👉 www.linkedin.com/company/deci... #ClinicalResearch #DECISIONproject

Consider joining this event by @a-tango.bsky.social and @crowdhelix.com! "Industrial Perspective on Drug Development Challenges for Clinical Trials" 📅 4th June 2025 🕚 11:00 am CEST / 🕙 10:00 am BST Register via this link: inevent.uk/en/Crowdheli...

It’s #ClinicalTrialsDay! At DECISION, we’re proud of our COMBAT & PROSPECT trials advancing care in decompensated cirrhosis. 💡COMBAT Q&A videos in multiple languages help engage patients ➡️ www.youtube.com/playlist?lis... Thanks to all who make our trials possible! #LiverResearch

✨ #PosterTour today at #EASLCongress 2025: All our 3 Horizon2020 #LiverResearch projects in 1 session! Topic: #Cirrhosis & #PortalHypertension Chair: Maria Papp 💡 Big moments: #AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan) #Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)

Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin #POSTER SAT-145-YI by Enrico Pompili (UNIBO) proposes a personalized management approach for patients with cirrhosis and ascites, based on real-world data from long-term albumin therapy. #EASL2025

🩺 Impact of diabetes mellitus on clinical outcomes in patients with acutely decompensated cirrhosis #E_POSTER SAT-184-YI by Mimma Bonomo (UNITO) explores how coexisting diabetes mellitus affects prognosis in patients hospitalized with acute decompensation of cirrhosis. #EASL2025

🦠The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course #POSTER SAT-518 by @beccsipollsi.bsky.social from @rwth.bsky.social at #EASL2025 @brunslab.bsky.social @easlnews.bsky.social

🧪 Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes #POSTER SAT-122-YI by Alberto Calleri (UNITO) examines how acute kidney disease affects outcomes in patients with acutely decompensated cirrhosis. 📅 Presented at #EASLCongress | #EASL2025 @easlnews.bsky.social

❤️ Cardiac performance is impaired in patients with proven alcohol-related hepatitis and predicts 3-month mortality in this patient population #POSTER SAT-503-YI by Pierre-Emmanuel Rautou (@inserm.fr, APHP, EF CLIF) 📅 Presented at the #EASLCongress | #EASL2025 @easlnews.bsky.social

Back in the Abstract Session: Theresa Wirtz presents her scRNA-seq work on monocyte subsets and ACLF risk. @rwth.bsky.social @brunslab.bsky.social @easlnews.bsky.social #Cirrhosis #ACLF #EASL2025"

Estefania Huergo presents methylation data in AD patients, selected as best Young Investigator abstract in Basic Science at #EASL2025 - Congrats! 🎉 @navarrabiomed.bsky.social @easlnews.bsky.social #Epigenetics #LiverResearch

Javier Fernandez (FCRB) is giving the hepatologist perspective on management of MDR infections in cirrhosis as part of the EASL/ESCMID Symposium: MDR infections - a challenge in decompensated cirrhosis at #EASL2025 #LiverDisease #Cirrhosis #Hepatology @easlnews.bsky.social

Is the etiological work-up of #PSVD a one-size-fits-all? DECISION consortium member Lucile Moga from APHP takes part in EASL/ VALDIG's session on "Do's and Don'ts in the management of Porto-Sinusoidal Vascular Disease". #EASLCongress #EASL2025 #LiverResearch @easlnews.bsky.social

How do you build&lead a successful research team? The next generation of PIs learned straight from the best in today's workshop “How to Start a Research Group: From Postdoc to PI" as @rautoupe.bsky.social shared practical insights on building&maintaining a high-performing team. @inserm.fr #EASL2025

DECISION consortium member Sophie Lotersztajn from the French research institute @inserm.fr at a late-afternoon abstract session today at #EASLCongress in Amsterdam, the Netherlands, about #fibrosis, #hepatocyte and #liver #regeneration. 🩺 #EASL2025 @easlnews.bsky.social

🔬 #POSTER FRI-222 by Thierry Gustot (EF CLIF) proposes one-week criteria to assess the appropriateness of continuing intensive care in ACLF patients who are not candidates for liver transplantation. #EASL2025 @easlnews.bsky.social

📊 Fibroblast growth factor 19 (FGF-19) predicts transplant free-survival in critically ill patients with acute-onchronic liver failure #POSTER FRI-199 by @beccsipollsi.bsky.social 📅 #EASLCongress | #EASL2025 @easlnews.bsky.social

🧊 Hypothermic oxygenated machine perfusion (HOPE) treatment prior to organ transplant alters key immune modulators in patients receiving liver transplantation #POSTER FRI-495-YI by @beccsipollsi.bsky.social 📅 #EASLCongress | #EASL2025 @brunslab.bsky.social @easlnews.bsky.social

Greetings from the DECISION Investigator Meeting at #EASL2025: Study updates and collaborative discussions with Paolo Caraceni & @rautoupe.bsky.social #ClinicalTrials #cirrhosis

Lastly at DECISION's Networking Session, Richard Moreau shares new data: high-throughput omics reveals biomarkers for infection & poor outcomes in cirrhosis. @inserm.fr @easlnews.bsky.social sky.social #Metabolomics #Cytokinomics #EASL2025

Next at the DECISION Networking Session at #EASL2025, Theresa Wirtz (UKA) presents scRNA-seq data showing a monocyte subset linked to ACLF risk. Fascinating translational science in action! @brunslab.bsky.social ky.social @easlnews.bsky.social ky.social #scRNAseq #ACLF

Kicking off our #EASL2025 Networking Session with an intro to the DECISION project by coordinator Pierre-Emmanuel Rautou - Let’s talk systems medicine, cirrhosis, and precision care! @rautoupe.bsky.social pe.bsky.social @easlnews.bsky.social ky.social #LiverDisease

Good morning! DECISION coordinator Pierre-Emmanuel Rautou just started the early morning abstract session on #cirrhosis at the #EASLCongress in Amsterdam. You can still join in the Benhamou Room until 09.45am! @easlnews.bsky.social

#LIVE now at #EASL2025! ⏰ 17:00 - 18:15, McIntyre Room 🧬 Learn more in this Abstract Session about "Rare Liver Diseases"! From #Genetics to #Clinical #Innovation, rare liver diseases are taking the center stage in this focused hepatology session. Chaired by Pavel Strnad from @rwth.bsky.social.

🧬Poster THU-159-YI Can dimethylarginines (DAS) predict #ACLF before it strikes? At #EASL2025, Kohilan Gananandan (@ucl.ac.uk) presents new data validating DAS as a biomarker for pre-ACLF and outcome prediction post-acute #decompensation in two large EU cohorts. #Biomarkers #Cirrhosis #LiverResearch

"Real-world experience with long-term albumin in patients with cirrhosis and asscites" was a fascinating session. @Enrico Pompili (Bologna University) discussed long-term #albumin therapy in #cirrhosis with #ascites. Don't miss the Poster SAT-145-YI on Saturday! #ClinicalInsights #EASL2025

🤝 We’re live at the EF CLIF Networking Session at #EASL2025! Partners and collaborators are gathering to exchange insights on cirrhosis and its complications, building bridges between research and clinical innovation. 📍 Cirrhosis & Complications Track Hub @easlnews.bsky.social

🩺10 year short-term outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis #POSTER WED-340 by Kohilan Gananandan (UCL) reports on a decade-long structured approach using low-dose thrombolysis for acute thrombosis #EASL2025

🧬 Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease: long-term efficacy and safety results from a phase 2 extension study #POSTER WED-323 by Pavel Strnad (UKA) #EASL2025 @rwth.bsky.social

📊 Validation of Baveno VII criteria for non-invasive diagnosis of clinically significant portal hypertension: systematic review and individual patient data meta-analysis #POSTER WED-512-YI by Juan Bañares (Vall d’Hebron BCN) assesses accuracy of BavenoVII through analysis of patient data #EASL2025

🧪 Treatment response to Terlipressin in patients with acute kidney injury hepatorenal syndrome and preexisting chronic kidney disease – the German liver cirrhosis / CKD-Terli study group #POSTER WED-194-YI by Frank Erhard Uschner @frankuschner.bsky.social (UM) #EASL2025

Excited for next week's #EASL2025 in Amsterdam! 💬 Don’t miss our Networking Session 📍 EASL Cirrhosis & Complications Track Hub 📅 9. May, 10-10:30h 🧭 Discover findings on immune cell profiling & multi-omics biomarker discovery in patients with decompensated #cirrhosis @easlnews.bsky.social

What a fruitful day at the 11th DECISION Steering Committee Meeting in Barcelona! From insightful discussions on #AcuteDecompensation (AD) to deep dives into our ongoing COMBAT & PROSPECT studies, we’ve covered important topics and set the path for the next half year. 🙌

We're all set in Barcelona for the 11th #DECISIONproject Steering Committee Meeting! ☕️📊 The room is ready, the agenda is packed, and we’re kicking things off shortly. Let’s make it a great day of science and collaboration! 💡🧬 #LiverResearch #SCMeeting

🧭 Gearing Up for the 11th SC Meeting in #Barcelona! Looking forward to a rich and productive day of exchange; with updates from our clinical studies COMBAT and PROSPECT, deep dives into systems-level analyses, and dedicated sessions on our manuscripts. #decompensatedcirrhosis

📢 On this 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗮𝘆 𝗼𝗳 𝗪𝗼𝗺𝗲𝗻 𝗮𝗻𝗱 𝗚𝗶𝗿𝗹𝘀 𝗶𝗻 𝗦𝗰𝗶𝗲𝗻𝗰𝗲, we celebrate the brilliant women driving innovation and discovery in DECISION! 👩‍🔬 They shape the future of #liverresearch! @idibaps.bsky.social @hospitalclinic.bsky.social @rwth.bsky.social @navarrabiomed.bsky.social @easlnews.bsky.social

What a year 2024! Highlights include: 📄 2 key publications: - A reproducible rat model for decompensated MASH-cirrhosis - ClustALL: Novel stratification in #cirrhosis 💡 First patient enrolled in the COMBAT trial! Thank you to all collaborators—here’s to 2025! 🎉 #LiverResearch

As the liver community on Bluesky is growing, we're excited to see more and more familiar faces from our consortium over here. We've created a Starter Pack of DECISION member institutions and researcher. #liversky

Hi! We're the DECISION consortium, an EU-funded research project striving to better understand the #pathophysiology of decompensated #cirrhosis leading to acute-on-chronic liver failure ( #ACLF ) at the systems level. We're 21 institutions form 10 European countries 💪